Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
581.74
+11.86 (2.08%)
At close: May 12, 2026, 4:00 PM EDT
584.82
+3.08 (0.53%)
After-hours: May 12, 2026, 7:13 PM EDT
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
| Name | Position |
|---|---|
| Dr. Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation |
| Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman & CEO |
| Harrison Silvers | Manager of Investor Relations |
| Mr. Gil Golden | Senior VP & Chief Medical Officer |
| Mr. James C. Edgemond | CFO & Treasurer |
| Mr. Michael I. Benkowitz | President & COO |
| Mr. Paul A. Mahon J.D. | Executive VP, General Counsel & Corporate Secretary |
| Ms. Holly Hobson | Associate Vice President of Human Resources |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 8-K | uthr-20260506.htm |
| 2026-05-06 | 10-Q | uthr-20260331.htm |
| 2026-04-29 | DEFA14A | uthr2026-defa14a.htm |
| 2026-04-29 | DEF 14A | uthr2026_courtesy-pdf.pdf |
| 2026-03-30 | 8-K | tm2610558d1_8k.htm |
| 2026-03-09 | 8-K | tm268321d1_8k.htm |
| 2026-03-02 | 8-K | tm267696d1_8k.htm |
| 2026-02-25 | 8-K | uthr-20260225.htm |
| 2026-01-22 | 8-K | tm263500d1_8k.htm |
| 2025-10-29 | 10-Q | uthr-20250930.htm |